North America holds a strong position in the tyrosine kinase inhibitor market, driven by heavy investment in oncology research and development. Leading cancer centers and academic institutions play an active role in advancing next-generation inhibitors and combination regimens. Growing use of genomic profiling is expanding the eligible patient pool. According to The Insight Partners, the...